Welcome to our dedicated page for Sino Biopharmaceutical news (Ticker: SBHMY), a resource for investors and traders seeking the latest updates and insights on Sino Biopharmaceutical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sino Biopharmaceutical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sino Biopharmaceutical's position in the market.
Akeso, Inc. announced that its co-developed anti PD-1 monoclonal antibody, Penpulimab, received marketing approval from China's NMPA for treating relapsed or refractory classic Hodgkin's lymphoma. This approval follows a pivotal trial showing an impressive objective response rate of 89.4% and a complete response rate of 47.1%. The drug's safety profile indicates low serious adverse events, with a median treatment duration of 14.8 months. Akeso is pursuing additional approvals for Penpulimab for various cancers in China and the U.S., highlighting its potential in oncology.
FAQ
What is the current stock price of Sino Biopharmaceutical (SBHMY)?
What is the market cap of Sino Biopharmaceutical (SBHMY)?
